Infections resistant to standard medicines enhance antibiotic therapy prices (Getty Photos)
ICMR researchers reveal a transparent mortality danger linked to drug-resistant infections in a serious new examine. The findings present these infections elevate demise charges, therapy prices and hospital stays throughout Indian tertiary hospitals. Antimicrobial resistance (AMR) now claims extra lives and sources than beforehand acknowledged. Docs and policymakers should act on prevention, quicker analysis and accountable antibiotic use.
The info come from a big multi-centre evaluation revealed in main medical journal The Lancet Regional Well being – South-East Asia. This proof strengthens the pressing case for stronger infection-control measures nationwide.
Key Highlights
- ICMR examine of 1.6 lakh hospital sufferers finds drug-resistant Gram-negative infections elevate mortality by a number of proportion factors.
- 61.1% of analyzed infections present resistance to carbapenems, as soon as thought of last-resort antibiotics.
- Resistant infections enhance antibiotic therapy prices 1.1-2 occasions and extend hospital stays.
Massive Multi-Hospital Evaluation Confirms Increased Dying Threat
The Indian Council of Medical Analysis analysed knowledge from 1.6 lakh hospitalized sufferers handled at 20 tertiary-care hospitals between April 2022 and April 2025. Of those, 26,213 sufferers developed infections brought on by 4 main Gram-negative micro organism: E. coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa. Researchers in contrast outcomes between resistant and prone strains of the identical micro organism. Mortality stands greater in each resistant group. The mortality price for E-coli infections brought on by resistant strains was 24.4%, in comparison with 17.3% for frequent strains. Equally, the mortality price for resistant Okay. pneumoniae infections was 31.2%, in comparison with 23.5% for frequent infections:
| Micro organism | Resistant Mortality | Vulnerable Mortality |
| Okay. pneumoniae | 31.2 per cent | 23.5 per cent |
| E. coli | 24.4 per cent | 17.3 per cent |
| A. baumannii | 37.9 per cent | 32.8 per cent |
| P. aeruginosa | 28.9 per cent | 20.2 per cent |
Drug-resistant infections drive up healthcare bills. Antibiotic therapy prices run 1.1 to 2 occasions greater for resistant instances. Sufferers with resistant infections additionally keep longer in hospital. These with resistant E. coli, for instance, stay a mean of 23.1 days in contrast with 17.8 days for prone instances.
“Antimicrobial resistance is now not a distant risk—it’s already costing Indian lives,” stated Dr Kamini Walia, senior scientist from ICMR and an writer of the examine. “Our examine reveals that carbapenem-resistant infections carry considerably greater mortality and therapy prices,” she stated, including that the reply isn’t merely extra highly effective antibiotics, however “higher an infection prevention, well timed diagnostics and accountable antibiotic use”.
Consultants Name for Stronger Prevention and Stewardship
Essential-care specialists be aware that hospitals more and more encounter carbapenem-resistant infections. Figuring out the organism and its resistance sample by typical tradition testing typically takes a number of days. Molecular diagnostics can pace this course of. Sufferers may have antibiotic combos, additional elevating prices. Researchers warning that the examine covers tertiary hospitals treating many critically unwell and referred sufferers. Findings subsequently don’t replicate efficiency of particular person hospitals.
Supply:
https://www.icmr.gov.in/icmrobject/custom_data/pdf/resource-guidelines/AMR_Annual_Report_2021.pdf
